TY  - BOOK
AU  - Alaa Amr Gad
AU  - Hoda Ali Sadek , 
AU  - Laila Abdalrahman Hegazy , 
AU  - Mona Salah Aldin Hamdy , 
TI  - Quantitative RT-PCR study of TAp73 and xNp73 in benign and malignant lymphoid lesions / 
PY  - 2013///
CY  - Cairo : 
PB  - Alaa Amr Gad , 
KW  - Benign and Malignant Lymphoid Lesions
KW  - RT-PCR
KW  - TAp73 and xNp73
N1  - Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology; Issued also as CD
N2  - Background: p73 is a member of the p53 family of tumor suppressors. Transactivating isoforms of p73 (TAp73) have p53-like, anti-proliferative and pro-apoptotic activities that are crucial for an efficient chemotherapy response. However, in contrast to p53, which is commonly inactivated in human cancer by point mutations, the TP73 gene is almost never mutated. Instead, the tumor suppressor activity of TAp73 is inhibited through a variety of mechanisms including epigenetic silencing and complex formation with inhibitory proteins. All these mechanisms have in common that they are in principle reversible and therefore amenable to therapeutic intervention. The use of 2 promoters at the N-terminus allows the expression of an isoform containing (TAp73) or not containing (xNp73) a complete N terminal transactivation domain, with the latter isoform capable of a dominant negative effect over the former
ER  -